• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Sonnet BioTherapeutics Holdings Inc.

    9/29/25 4:05:39 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SONN alert in real time by email
    false 0001106838 0001106838 2025-09-26 2025-09-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 26, 2025

     

    Sonnet BioTherapeutics Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-35570   20-2932652

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    100 Overlook Center, Suite 102

    Princeton, NJ

      08540
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (609) 375-2227

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   SONN   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On September 26, 2025, Sonnet BioTherapeutics Holdings, Inc. (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting were the following proposals: (1) to elect five directors to the Company’s Board of Directors (the “Board”) to hold office for the following year until their successors are elected, (2) to approve, on an advisory basis, the executive compensation of the Company’s named executive officers (the “Named Executive Officers”) as described in the proxy statement (3) to vote, on an advisory basis, on how frequently the Company should seek approval from its stockholders, on an advisory basis, of the compensation paid to the Named Executive Officers, and (4) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending September 30, 2025.

     

    At the Annual Meeting, the foregoing stockholder proposals were approved, based upon an aggregate of 6,827,352 shares of Common Stock outstanding as of August 26, 2025, which was the record date for the Annual Meeting. The final voting results were as follows:

     

    1. The votes cast with respect to the proposal to elect five directors to the Board to hold office for the following year until their successors are elected were as follows:

     

       For   Withheld  

    Broker

    Non-Votes

     
    Raghu Rao   1,220,258    325,245    2,152,189 
    Donald Griffith   957,147    588,356    2,152,189 
    Nailesh Bhatt   1,220,922    324,581    2,152,189 
    Albert Dyrness   958,237    587,266    2,152,189 
    Lori McNeill   1,222,090    323,413    2,152,189 

     

    2. The proposal to approve, on an advisory basis, the executive compensation of the Company’s Named Executive Officers as described in the proxy statement was approved by a majority of the votes cast at the Annual Meeting, based upon the following votes:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes 
    1,209,407    330,412    5,678    2,152,195 

     

    3. The votes cast will respect to the proposal to determine, on an advisory basis, the preferred frequency the Company should seek approval from its stockholders, on an advisory basis, of the compensation paid to the Named Executive Officers were as follows:

     

    One Year   Two Years   Three Years   Abstentions   Broker Non-Votes 
    1,394,436    60,801    88,271    1,995    2,152,189 

     

    4. The proposal to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending September 30, 2025 was approved by a majority of the votes cast at the Annual Meeting, based upon the following votes:

     

    Votes For   Votes Against   Abstentions 
    3,181,107    495,000    21,585 

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Sonnet BioTherapeutics Holdings, Inc.
         
    September 29, 2025 By: /s/ Raghu Rao
      Name: Raghu Rao
      Title: Interim Chief Executive Officer

     

     

    Get the next $SONN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SONN

    DatePrice TargetRatingAnalyst
    2/9/2022$5.00 → $2.00Buy
    BTIG
    12/20/2021$8.00 → $2.50Buy
    Chardan Capital
    12/16/2021$2.00Buy
    HC Wainwright & Co.
    9/15/2021$5.00Buy
    BTIG
    More analyst ratings

    $SONN
    SEC Filings

    View All

    SEC Form 8-K filed by Sonnet BioTherapeutics Holdings Inc.

    8-K - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

    9/29/25 4:05:39 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Sonnet BioTherapeutics Holdings Inc.

    DEF 14A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

    8/26/25 5:01:29 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Sonnet BioTherapeutics Holdings Inc.

    10-Q - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Filer)

    8/13/25 4:06:40 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sonnet to Present at the MedInvest Biotech & Pharma Conference

    PRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that Raghu Rao, Interim Chief Executive Officer of Sonnet, will present on Thursday, September 25, 2025 at 9:40 AM PT at the MedInvest Biotech & Pharma Conference being held in Palo Alto, California. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conferenc

    9/19/25 9:00:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet Releases Virtual Investor "What This Means" Segment

    - Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221) - Watch the "What This Means" video here PRINCETON, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a Virtual Investor "What This Means" segment.As part of the segment, Dr. Richard Kenney, Chief Medical Officer, discussed its recent update on its SB221 clinical trial including that a) enrollment of

    8/11/25 9:15:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

    Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, cytokine, and efficacy data suggest a strong potential for clinical benefit using the current maximum dose of SON-1010 A second patient with PROC in the E6 combination cohort recently had a confirmed PR, so 2 out of 3 total patients had a tumor response at that dose After completing enrollment of the expansion group at that top dose, a new E7 cohort has been added to examine the safety and effectiveness of a 25% higher maintenance dose of SON-1010 PRINCETON, N.J., Aug. 04, 2025 (GLOBE NEW

    8/4/25 8:40:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG reiterated coverage on Sonnet BioTherapeutics with a new price target

    BTIG reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00 from $5.00 previously

    2/9/22 6:54:44 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital reiterated coverage on Sonnet BioTherapeutics with a new price target

    Chardan Capital reiterated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.50 from $8.00 previously

    12/20/21 8:31:50 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Sonnet BioTherapeutics with a new price target

    HC Wainwright & Co. initiated coverage of Sonnet BioTherapeutics with a rating of Buy and set a new price target of $2.00

    12/16/21 8:15:32 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mohan Pankaj bought 34,375 shares, increasing direct ownership by 137% to 59,526 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    10/27/23 8:00:08 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rao Raghu bought 15,625 shares, increasing direct ownership by 1,315% to 16,813 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    10/27/23 8:00:10 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Medical Officer Kenney Richard T

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    8/21/25 4:48:43 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Kenney Richard T was granted 8,000 shares, increasing direct ownership by 582% to 9,374 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    7/15/25 7:35:19 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bhatt Nailesh was granted 10,000 shares, increasing direct ownership by 1,828% to 10,547 units (SEC Form 4)

    4 - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Issuer)

    7/15/25 7:35:19 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Leadership Updates

    Live Leadership Updates

    View All

    Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

    PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of Directors has unanimously approved the appointment of current board member Raghu Rao, as Interim Chief Executive Officer of the Company, and the promotion of Stephen McAndrew, Ph.D., the Company's current Chief Business Officer, to President and Chief Business Officer of the Company. The Board intends

    4/1/25 7:30:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

    PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. Dr. McAndrew brings more than 30 years of experience with various business models and types of transactional agreements involving biologics at different stages of development. During the course of his tenure at Sonnet, Dr. McAndrew has served as Vice President and then Senior Vice President, Business Development, and has been responsible for developing and leading the Compa

    2/13/25 8:30:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee

    Ms. McNeill is a former executive of Pfizer and an entrepreneur with expertise in marketing and public relations; she will sit on the Board of Directors and serve as the Chairperson of Sonnet's newly formed Business Advisory Committee (BAC)The BAC will advise the company on business collaborations, communications and interactions with the Federal GovernmentPRINCETON, NJ / ACCESSWIRE / September 26, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that Lori McNeill has been appointed to the Company's Board of Directors. Ms. McNeill's Board position will also round out the composition of the compan

    9/26/22 8:00:00 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SONN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

    SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

    1/2/24 4:19:28 PM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

    SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

    11/17/23 11:32:52 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Sonnet BioTherapeutics Holdings Inc. (Amendment)

    SC 13G/A - Sonnet BioTherapeutics Holdings, Inc. (0001106838) (Subject)

    11/6/23 11:35:23 AM ET
    $SONN
    Biotechnology: Pharmaceutical Preparations
    Health Care